Hualan Biological Engineering Inc. (SHE:002007)
China · Delayed Price · Currency is CNY 13.44
-0.04 (-0.30%)
Jul 31, 2026, 3:04 PM CST
SHE:002007 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 4,490 | 4,595 | 4,379 | 5,342 | 4,517 | 4,436 |
Revenue Growth | 0.67% | 4.93% | -18.02% | 18.26% | 1.82% | -11.69% |
Gross Profit Gross Profit Growth | 2,476 | 2,582 | 2,611 | 3,615 | 2,818 | 2,898 |
Operating Income Operating Income Growth | 1,034 | 1,130 | 1,179 | 1,810 | 1,223 | 1,586 |
Net Income Net Income Growth | 857.61 | 940.4 | 1,088 | 1,482 | 1,076 | 1,299 |
Earnings Per Share EPS Growth | 0.47 | 0.52 | 0.59 | 0.81 | 0.59 | 0.71 |
EPS Growth | -24.62% | -13.41% | -26.75% | 37.92% | -17.00% | -19.95% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Blood Product Blood Product Growth | 3,387 | 3,246 | 2,926 | 2,679 | 2,598 |
Vaccine Product Vaccine Product Growth | 1,195 | 1,117 | 2,405 | 1,818 | 1,825 |
Others Others Growth | 12.88 | 16.34 | 10.89 | 20.21 | 13.86 |
Total Total Growth | 4,595 | 4,379 | 5,342 | 4,517 | 4,436 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 3,767 | 4,403 | 5,398 | 4,322 | 3,708 | 3,352 |
Total Debt Total Debt Growth | 8.87 | 455.78 | 908.88 | 1,010 | 1,110 | 1,001 |
Net Cash (Debt) Net Cash Growth | 3,758 | 3,947 | 4,489 | 3,312 | 2,598 | 2,351 |
Net Cash Growth | -24.02% | -12.07% | 35.54% | 27.50% | 10.51% | -35.14% |
Net Cash Per Share Net Cash Per Share Growth | 2.06 | 2.16 | 2.46 | 1.82 | 1.42 | 1.28 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 857.39 | 877.96 | 1,059 | 1,346 | 957.31 | 1,432 |
Capital Expenditures CapEx Growth | -181.15 | -197.31 | -255.43 | -753.41 | -393.95 | -811.35 |
Free Cash Flow Free Cash Flow Growth | 676.24 | 680.65 | 803.92 | 592.43 | 563.36 | 621.15 |
Free Cash Flow Growth | -16.55% | -15.33% | 35.70% | 5.16% | -9.30% | -11.75% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 55.16% | 56.19% | 59.62% | 67.67% | 62.38% | 65.33% |
Operating Margin | 23.03% | 24.58% | 26.92% | 33.89% | 27.08% | 35.76% |
Pretax Margin | 24.02% | 25.54% | 30.57% | 38.89% | 31.62% | 38.06% |
Profit Margin | 19.10% | 20.47% | 24.84% | 27.73% | 23.83% | 29.28% |
FCF Margin | 15.06% | 14.81% | 18.36% | 11.09% | 12.47% | 14.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 1.000 | 1.000 | 0.200 | 0.300 | 0.300 | 0.200 |
Dividend Per Share Growth | 400.00% | 400.00% | -33.33% | 0% | 50.00% | -33.33% |
Dividend Yield | 7.44% | 6.87% | 1.29% | 1.50% | 1.48% | 0.78% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 28.62 | 29.40 | 28.33 | 27.32 | 38.36 | 40.93 |
Forward PE | 24.44 | 15.93 | 19.37 | 23.05 | 28.47 | 27.36 |
P/FCF Ratio | 36.29 | 40.62 | 38.33 | 68.31 | 73.28 | 85.59 |
PS Ratio | 5.47 | 6.02 | 7.04 | 7.58 | 9.14 | 11.98 |